克洛巴扎姆
左乙拉西坦
入射(几何)
医学
药品
药理学
麻醉
皮肤病科
癫痫
精神科
物理
光学
作者
Nikhita R. Kichili,Alyssa Hansen,Dheeraj Kagithala,Ayezel Munoz Gonzalez,Michael G. Wilkerson
标识
DOI:10.1016/j.anai.2024.02.003
摘要
The FDA recently issued a statement requiring manufacturers of levetiracetam and clobazam to include warnings regarding drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) to patients and their caregivers.1 Levetiracetam, an anti-epileptic, is rarely associated with DiHS/DRESS, and clobazam, a benzodiazepine prescribed as an anxiolytic and anti-epileptic, has recently been linked to DiHS/DRESS.2-5 It is estimated that over 12 million prescriptions of levetiracetam and 750,000 prescriptions of clobazam were filled in 2022 in the United States.1 Exploring cases of DiHS/DRESS related to levetiracetam and clobazam in the FDA Adverse Event Reporting System (FAERS) database and current literature yielded 32 cases associated with levetiracetam and 10 cases associated with clobazam.1
科研通智能强力驱动
Strongly Powered by AbleSci AI